Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) – Equities research analysts at Zacks Investment Research reduced their FY2017 earnings per share (EPS) estimates for Eyegate Pharmaceuticals in a research note issued to investors on Monday. Zacks Investment Research analyst B. Marckx now anticipates that the specialty pharmaceutical company will earn ($1.05) per share for the year, down from their previous forecast of ($0.97). Zacks Investment Research also issued estimates for Eyegate Pharmaceuticals’ Q4 2017 earnings at ($0.26) EPS and FY2018 earnings at ($0.61) EPS.

Separately, HC Wainwright set a $6.00 price objective on Eyegate Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, August 2nd.

Shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at $1.10 on Wednesday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.81 and a current ratio of 0.81. Eyegate Pharmaceuticals has a 52 week low of $0.90 and a 52 week high of $3.90.

An institutional investor recently raised its position in Eyegate Pharmaceuticals stock. Vanguard Group Inc. increased its stake in Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) by 0.8% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 247,319 shares of the specialty pharmaceutical company’s stock after acquiring an additional 1,988 shares during the period. Vanguard Group Inc. owned approximately 2.27% of Eyegate Pharmaceuticals worth $339,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 11.94% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “FY2017 Earnings Forecast for Eyegate Pharmaceuticals, Inc. (EYEG) Issued By Zacks Investment Research” was originally published by American Banking News and is owned by of American Banking News. If you are accessing this story on another website, it was illegally copied and republished in violation of United States and international copyright laws. The correct version of this story can be viewed at https://www.americanbankingnews.com/2017/11/29/fy2017-earnings-forecast-for-eyegate-pharmaceuticals-inc-eyeg-issued-by-zacks-investment-research.html.

Eyegate Pharmaceuticals Company Profile

Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.

Earnings History and Estimates for Eyegate Pharmaceuticals (NASDAQ:EYEG)

Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.